PerkinElmer, Inc. (NYSE: PKI), a leading provider of drug discovery, life science research, and analytical solutions, and Luminex(R) Corporation (Nasdaq: LMNX), a leading multiplex solution developer, announced today a long-term licensing agreement to provide PerkinElmer access to Luminex’s xMAP(R) technology and assay development capabilities of the Luminex Bioscience Group.
